Supplements

Golimumab reduces disease activity and improves quality of life in patients with axial spondyloarthritis

Golimumab, an anti-TNF-alpha antibody, is effective in reducing disease activity, back pain, sleep disruption, and fatigue in axial spondyloarthritis, while improving quality of life and work productivity. Real-world studies and post hoc analyses support these benefits, with a favorable safety profile consistent with other TNF inhibitors.

1 min read•Updated Aug 13, 2026•1 RCTs•View structured evidence →
Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Golimumab reduces disease activity and improves quality of life in patients with axial spondyloarthritis The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).

The Claim

Golimumab reduces disease activity and improves quality of life in patients with axial spondyloarthritis

This conclusion is most relevant to: Patients with axial spondyloarthritis (including those from pivotal RCTs and real-world studies).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits. (Advances in therapy, 2026) —

How It Works

The proposed biological pathway:

  • ▸Golimumab binds to and inhibits tumor necrosis factor alpha (TNF-alpha)
  • ▸Reduction of pro-inflammatory cytokine activity
  • ▸Decreased inflammation in sacroiliac joints, spine, and entheses
  • ▸Reduced pain, fatigue, sleep disruption, and improved function and quality of life

Who Might Benefit

Evidence fit by population:

  • ▸Patients with axial spondyloarthritis (including those from pivotal RCTs and real-world studies)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Narrative review, not a systematic review or meta-analysis
  • ▸Abstract does not provide specific effect sizes or statistical significance values
  • ▸Real-world data may be subject to selection bias and confounding

Frequently Asked Questions

What is golimumab used for?▼

Golimumab is used for the treatment of axial spondyloarthritis, an inflammatory disease affecting the spine and sacroiliac joints.

Does golimumab improve sleep disruption in axial spondyloarthritis?▼

Yes, according to the review, golimumab decreased sleep disruption in patients with axial spondyloarthritis.

What are the common side effects of golimumab?▼

The safety profile is favorable, with adverse events consistent with other TNF-alpha inhibitors, but specific side effects are not detailed in the abstract.

How does golimumab work?▼

Golimumab inhibits tumor necrosis factor alpha, a pro-inflammatory cytokine involved in the pathogenesis of axial spondyloarthritis.

References

  1. 1.Deodhar A, Kim TJ, Navarro-Compán V, Fonseca S, Antunes J, Singh A, Milek R, Wu J, Ramiro S. “Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits..” Advances in therapy, 2026. PMID: 42573952 DOI: 10.1007/s12325-026-03742-w
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.